Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high morbidity and mortality; most patients die within three to five years following diagnosis. Pirfenidone (Roche’s Esbriet) and nintedanib (Boehringer Ingelheim’s Ofev) are the only two drugs approved for treatment of adults with IPF. In addition to these two disease-modifying therapies (DMTs), physicians prescribe off-label medications (e.g., corticosteroids, anticoagulants) to treat IPF patients when the risk/benefit profile does not warrant treatment with pirfenidone or nintedanib, or when patients cannot access these DMTs. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for IPF.

Questions Answered

  • What patient share do key therapies and brands garner by line of treatment in newly diagnosed IPF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IPF patients?
  • What proportion of IPF patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of IPF patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with IPF ?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Idiopathic Pulmonary Fibrosis Treatment Algorithms Claims Data Analysis US 2020

Author(s): John Crowley

John leads DRG’s Infectious, Niche, & Rare Diseases team and manages the market research portfolio across niche and rare diseases, anti-infectives, and vaccines. Prior to his current role, he was a Director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. John holds a from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute.


Related Reports

Idiopathic Pulmonary Fibrosis | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key idiopathic pulmonary f...

View Details

Idiopathic Pulmonary Fibrosis | Landscape & Forecast | Disease Landscape & Forecast

Although a rare disease, idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases (

View Details